India's regulator looks to relax clinical trial protocols in face of COVID-19 challenge

4 April 2020

Allowing deviation from protocol in clinical trials, the Indian government is looking to relax clinical trial rules in the country temporarily to let pharmaceutical companies develop a vaccine for the novel coronavirus.

In a notification, India’s Central Drugs Standard Control Organization (CDSCO) aid there are various challenges that might arise during the conduct of clinical trials in the wake of COVID-19.

The CDSCO notification adds that, since it would be difficult to adhere to all the protocol and regulations while conducting clinical trials of COVID-19 drugs in the country, researchers would be forced to make some modifications.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK